FEQ1 Stock Chart & Stats
€2.58
€0.01(0.39%)
At close: 4:00 PM EDT
€2.58
€0.01(0.39%)
Day’s Range― - ―
52-Week Range€2.13 - €3.19
Previous CloseN/A
Volume0.00
Average Volume (3M)92.00
Market Cap
€219.01M
Enterprise Value€291.18
Total Cash (Recent Filing)€21.58M
Total Debt (Recent Filing)€103.27M
Price to Earnings (P/E)49.3
Beta0.32
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding82,883,400
10 Day Avg. Volume278
30 Day Avg. Volume92
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Mix (products + CDMO)A dual revenue model combining proprietary product sales and CDMO services provides structural ballast to revenue streams. Contract manufacturing can deliver multi-year supply fees and utilization-linked cash, while product sales offer upside from brand uptake and pricing—reducing reliance on any single demand source.
Manufacturing And Development CapabilitiesOwning manufacturing and development capabilities creates durable competitive advantages: higher barriers to entry, ability to capture CDMO margin, and control over supply reliability. These assets support long-term client relationships and provide optionality to scale third‑party business as market demand evolves.
Historically Moderate Leverage And Equity GrowthA track record of moderate leverage and gradual equity growth gives the company structural resilience versus highly leveraged peers. This historical balance-sheet strength supports credit access for capex and contract fulfillment and provides a buffer to withstand cyclical revenue swings absent persistent cash deterioration.
Bears Say
Sharp 2025 Revenue And Margin DeteriorationA meaningful revenue drop and severe margin compression indicate structural demand or pricing pressure that can persist beyond a single year. Sustained lower volumes or pricing erode operating leverage, constrain reinvestment in products and services, and undermine long-term margin sustainability unless addressed by strategy shifts or cost restructuring.
Weak And Volatile Cash GenerationThe swing to negative free cash flow reduces the firm's ability to self-fund capex, R&D, and working capital, increasing reliance on external funding. Given prior FCF volatility, this raises structural funding risk and could limit competitive investments or contract capacity expansion unless cash conversion normalizes.
Rising Leverage In 2025 Increases Financial RiskAn uptick in debt-to-equity to ~0.45 alongside weaker earnings worsens financial flexibility. Higher leverage increases interest and covenant exposure, constraining strategic options and heightening refinancing risk during prolonged earnings weakness, which is a durable headwind if profitability does not recover.
LABORATORIO REIG JOFRE News
FEQ1 FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.13 and its highest was €3.19 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €219.01M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Nov 13, 2026 which is in 103 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
Currently, no data Available
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. does not currently pay dividends.
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,883,400 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in DE:FEQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Almirall
―
Clinica Baviera
―
Faes Farma
―
Grifols
―
Laboratorios Farmaceuticos Rovi
―